Finding High-Potential Drug Candidates
Pharmaceutical discovery has always involved looking for possible drug candidates that will work on specific targets. Traditionally, this has involved screening tens of thousands of small molecules to find those that will most strongly interact with the protein target. The newest wave of drugs, however, are based on large molecules—antibodies that are themselves proteins. So now the drug and the target are both proteins.
Agilent continually advances the state of the art for unambiguously identifying and validating protein biomarkers associated with human disease. We then help in the discovery of a biopharmaceutical product or antibody that hits the target in a way that alters the disease, which makes the product a high-potential drug candidate.